sb 203580 has been researched along with 4-phenyl-3-butenoic acid in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (4-phenyl-3-butenoic acid) | Trials (4-phenyl-3-butenoic acid) | Recent Studies (post-2010) (4-phenyl-3-butenoic acid) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 27 | 0 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, AM; Burns, TJ; Matesic, DF; May, SW; Ruch, RJ; Sidorova, TS; Tran, PL | 1 |
1 other study(ies) available for sb 203580 and 4-phenyl-3-butenoic acid
| Article | Year |
|---|---|
p38 MAPK activation, JNK inhibition, neoplastic growth inhibition, and increased gap junction communication in human lung carcinoma and Ras-transformed cells by 4-phenyl-3-butenoic acid.
Topics: Animals; Apoptosis; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexin 43; Epithelial Cells; Fatty Acids, Monounsaturated; Gap Junctions; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Liver; Lung Neoplasms; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Rats | 2012 |